Case Report

Ultrasound and molecular prenatal diagnosis of Beckwith-Wiedemann syndrome: Two case reports

Andrea de Vasconcelos Gaspar, MD\textsuperscript{a,}* , Miguel Branco, MD\textsuperscript{a} , Eulália Galhano, MD\textsuperscript{a} , Fabiana Ramos, MD\textsuperscript{a,}\textsuperscript{b}

\textsuperscript{a}Centro de Diagnóstico Pré-natal, Maternidade Bissaya Barreto, Centro Hospitalar e Universitário de Coimbra, Rua Prof. Mota Pinto, Coimbra 3004-561, Portugal
\textsuperscript{b}Medical Genetics Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

\textbf{A B S T R A C T}

Beckwith-Wiedemann syndrome (BWS) is a rare genetic disease, characterized by macrosomia, congenital malformations and tumor predisposition, associated with genetic and epigenetic alterations in the 11p15 region. Most cases are diagnosed after birth, with prenatal diagnosis being difficult and depending on the identification of specific ultrasound anomalies, namely macrosomia, macroglossia, omphalocele and renal dysplasia. Case 1: Ultrasound diagnosis at 13 weeks of isolated omphalocele with normal array. At 20 weeks, there were shortened fetal long bones, foot deformity, macroglossia, corpus callosum hypoplasia and bilateral nephromegaly. Due to the polymalformative syndrome, a termination of pregnancy (TOP) was performed. The anatomopathological study of the placenta identified mesenchymal dysplasia. The search for the methylation pattern of the 11p15 region by MS-MLPA was normal and the molecular study of the CDKN1C gene identified a likely pathogenic variant, inherited from the mother. Case 2: Morphological ultrasound at 21 weeks revealed macrosomia, macroglossia, omphalocele, bilateral renal dysplasia, and hydramnios. The cytogenetic study, after amniocentesis, was normal (46,XX karyotype). TOP was performed. The anatomopathological study of the fetus confirmed the described malformations and the one concerning the placenta identified placentomegaly. The search for the methylation pattern of the 11p15 region by MS-MLPA revealed abnormal methylation. These results confirmed the diagnosis of BWS in both cases. Prenatal ultrasound suspicion of this pathology is extremely important to guide the conduct in pregnancy and/or the prevention of perinatal complications. Shortened fetal long bones and foot deformity complement the broad spectrum of this syndrome. Positive molecular tests allow confirming the diagnosis, assessing the risk of recurrence and guiding the surveillance of future pregnancy.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Competing Interests: The authors declare that they have no conflicts of interest related to this work.

\textsuperscript{**} Funding: The authors declare that there are no sources of financing.

\textsuperscript{*} Corresponding author.

E-mail address: andreiadevasconcelosgaspar@gmail.com (A. de Vasconcelos Gaspar).

https://doi.org/10.1016/j.radcr.2022.09.066

1930-0433/© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{image.png}
\caption{Description of the image.}
\end{figure}
Introduction

Beckwith-Wiedemann syndrome (BWS) was first reported in 1963 by Beckwith and in 1964 by Wiedemann that described a unique syndrome in newborns, including omphalocele, macroglossia, overgrowth, renal hyperplasia, medullary dysplasia, adrenal cytomegaly, pancreatic islet hyperplasia, facial nevus flammeus, and hypoglycemia. Further others authors report maternal polyhydramnios in 50% of cases [1,2]. BWS has an incidence of 1 in 10,300-13,700 live births, with similar prevalence in females and males [3,4].

BWS exhibits etiological molecular heterogeneity. It usually occurs sporadically (85%), but familial transmission occurs in approximately 15% of cases. Different mechanisms can originate BWS by epigenetic and/or genomic alterations leading to abnormal methylation at 11p15.5 (loss of methylation on the maternal chromosome at imprinting center 2 (IC2) in 50% of affected individuals; paternal uniparental disomy in 20% and gain of methylation on the maternal chromosome at imprinting center 1 (IC1) in 5%) [5,6].

The syndrome presents a large clinical heterogeneity, generally including omphalocele, macroglossia, and macrosomia [2]. In the prenatal period, macrosomia, and hydramnios are the most frequent findings, and it is also associated with placental abnormalities [7].

There are few cases reported in the prenatal period, due to its difficult diagnosis, and those that do exist are old and poorly documented in terms of ultrasound images associated with the syndrome.

These 2 cases, in addition to being rare, demonstrate the correct diagnostic approach, ultrasonographic and molecular, in the prenatal period, in case of suspected BWS. Furthermore, the identification of shortened fetal long bones and foot deformity in one of the cases complements the broad spectrum of this syndrome.

Case presentation

Case 1: 38-year-old pregnant woman, Gravida III Parity I (one full term delivery by cesarean section, with male newborn (NB) weighing 3770 g, healthy; one early pregnancy loss), with no relevant personal history. She denied consanguinity or a family history of birth defects.

Pregnancy was early monitored in the hospital and primary health care. The analytical study of the first trimester did not show alterations, with all serologies being negative (immune to rubella, immune to toxoplasmosis, nonimmune to Cytomegalovirus, negative Hepatitis B and HIV).

She was referred for prenatal diagnosis at 13 weeks and 3 days for omphalocele and nuchal translucency greater than the 95th percentile for gestational age.

Chorionic villus sampling was performed. QF-PCR did not detect aneuploidies of chromosomes 13, 18, 21, and X and chromosome microarray analysis did not identify clearly pathogenic alterations.

Morphological ultrasound was performed at 20 weeks and 4 days, which revealed omphalocele (Fig. 1A), macroglossia (Figs. 1B and C), prefrontal edema (7 mm, Fig. 1D), corpus callosum hypoplasia (14.9 mm, <5th percentile, Fig. 1E), shortened long bones at 5th percentile (humerus with 28.2 mm, femur with 30.1 mm; Fig. 2), foot deformity with median curvature of its longest axis (Fig. 1F), not in relation to the tibia/fibula, and bilateral nephromegaly (right kidney measuring 19 × 19 × 33 mm, corresponding to 6.2 cm² and left kidney measuring 21 × 22 × 29 mm, with 7 cm³).

The hypothesis of BWS was raised and amniocentesis was performed to determine the methylation status of the 11p15 region by MS-MLPA, which was normal.

Due to polymalformative syndrome, termination of pregnancy (TOP) was requested by couple. The observation and anatomopathological study of the fetus confirmed the ultrasound findings, with partial agenesis of the corpus callosum, pancreas and large ovaries and cytomegaly of the adrenal glands.

The anatomopathological study of the placenta identified mesenchymal dysplasia.

For this reason, we carry out the molecular study of the CDKN1C gene, which identified a heterozygous probably pathogenic variant, c.479del [p. (Pro160Argfs*112)], inherited from the unaffected mother, which molecularly confirms the diagnosis of BWS.

Case 2: 35-year-old female, healthy, Gravida I Parity I a delivery by cesarean section, male NB, 3290 g, healthy, with no family history of congenital malformations. The pregnancy was monitored, without complications. The analytical study and ultrasound in the 1st trimester (12s+6d) showed no changes, with nuchal translucency below the 95th percentile (1.9 mm). The couple was not consanguineous.

She was referred to the prenatal diagnosis at 21 weeks and 6 days due to macrosomia (estimate fetal weight 642 g, >95th percentile), macroglossia, omphalocele, bilateral nephromegaly (right kidney with 29 × 21 × 50 mm, 15.9 cm² and left with 34 × 28 × 50 mm, 25.4 cm², both above the 95th percentile) and hydramnios (deepest vertical pocket of 7.3 cm) (Fig. 3).

Amniocentesis was performed at 22s+6d, and the cytogenetic study was normal (46, XX karyotype). The couple requested TOP, which was performed at 23 weeks. The anatomopathological study of the fetus confirmed the ultrasound findings, having identified left hemihypertrophy, macrostomia, omphalocele containing intestine, adrenal glands with bilateral cortical cytomegaly, large gallbladder, pancreatic hyperplasia, and the study of the placenta identified placental polymegaly.

The search for the methylation status of the 11p15 region by MS-MLPA (methylation of KCNQ1OT1 and H19 genes) revealed abnormal methylation, having confirmed the existence of loss of methylation in the imprinting center 2 (IC2) and methylation gain in the imprinting center 1 (IC1). These results confirmed the diagnosis of BWS.

Discussion

BWS is a rare disease, whose prenatal diagnosis requires a strong suspicion and knowledge of the key clinical findings.
Fig. 1 – (A) Omphalocele containing intestine (sagittal plane at the level of the fetal abdomen); (B) macroglossia (midsagittal plane of the face); (C) macroglossia (coronal view of upper lip); (D) prefrontal edema (sagittal plane of the face); (E) corpus callosum hypoplasia (midsagittal plane of the face); (F) foot deformity with medial curvature of its longest axis (transverse plane).

Fig. 2 – Femur and humerus growth curves, persistently at the 5th percentile or below.

Fig. 3 – (A) Omphalocele (transverse plane of the abdomen); (B) macroglossia (midsagittal plane of the face).
Table 1 – Diagnostic criteria of Beckwith-Wiedemann syndrome.

| Cardinal features (2 points per feature) | Suggestive features (1 point per feature) |
|----------------------------------------|------------------------------------------|
| Macroglossia                           | Birth weight >2 SDS above the mean         |
| Exomphalos                             | Polyhydramnios and/or placentalomegaly    |
| Hemihyperplasia                        | Nephromegaly and/or hepatomegaly          |
| Multifocal and/or bilateral Wilms tumor or nephroblastomatosis | Umbilical hernia and/or diastasis recti |
| Hyperinsulinism (lasting beyond 1 week and requiring escalated treatment) | Ear creases and/or pits                  |
| Pathology findings: adrenal cortex cystomegaly, placental mesenchymal dysplasia or pancreatic adenomatosis | Hypoplycemia                              |
|                                       | Facial nevus simplex                      |
|                                       | Typical BWS tumors (unilateral Wilms tumor rhabdomyosarcoma, neuroblastoma, hepatoblastoma, adrenocortical carcinoma or pheochromocytoma) |

There is no universal approach to the diagnosis of this pathology. Classically, the clinical diagnosis of BWS in postnatal is based on the presence of 3 major features (anterior abdominal wall defect, macroglossia, macrosomia) or 2 major and 3 minor features (ear creases on the lobes or postauricular pits, prominent facial nevus flammeus, nephromegaly, hemihyperplasia, or hypoglycemia) [8].

A recent international consensus, from 2018, created new diagnostic criteria based on cardinal and/or suggestive characteristics of the syndrome (Table 1).

According to this new classification, for the diagnosis of BWS a score ≥ 4 is required, with no need for genetic confirmation. Patients with scores greater than 2 require genetic testing for further investigation [9]. Some of these findings can be found in the prenatal period, but most are only detected after birth.

Ultrasound is a valuable tool in the prenatal detection of characteristic findings associated with BWS. The first prenatal diagnosis was made in 1980, after ultrasound description of fetus larger than expected with increased amniotic fluid, bilateral cystic kidneys and an apparent omphalocoele [10].

Previous case reports suggest that the prenatal diagnosis of BWS can be made during pregnancy through the following findings: macrosomia, macroglossia, omphalocoele, hydramnios, increased waist circumference, nephromegaly, or hepatomegaly [11].

Some authors have proposed criteria for prenatal diagnosis of BWS. However, the samples are small and the criteria used include anatomopathological data, so they are not very useful in clinical practice, especially if TOP is not an option for the couple [12].

Macrosomia was a consistent finding in both cases. It appears to occur in over 50% of fetuses diagnosed with BWS [8].

Macroglossia was a facial anomaly detected in both situations. It is one of the most frequent clinical features of the syndrome, with an incidence of 82%-98% [3,13]. It is usually only detected in the postpartum period, because it can appear later in fetal life or, according to some authors, because in the past, correct evaluation of the fetal face was not routinely performed [14,15].

The existence of an abdominal wall defect was another common feature among the cases. Omphalocoele affects about half of BWS cases, but only 3% of omphalocoele are associated with this syndrome [16].

Renal abnormalities associated with BWS are nephromegaly and pyelectasis [17]. In these cases, both fetuses had bilaterally enlarged kidneys.

Brain malformations, namely hydrocephaly, Chiari malformation and posterior fossa abnormalities have been reported associated with this pathology [18,19]. However, to our knowledge, anomalies of the corpus callosum have only been reported twice in the literature: a dysgenesis of the corpus callosum associated with a Dandy-Walker malformation and a hypoplasia of the corpus callosum [20].

Shortened long bones, below the 5th percentile, were found in the first case described. This is interesting, as this syndrome is associated with overgrowth. Although there is a case report in the literature with a short femur, there does not seem to be one with short humerus and femur [21]. To the best of our knowledge, this is the first clinical case with shortened long bones in BWS. Foot deformity with medial curvature of its longest axis does not seem to have been previously reported either.

Hydramnios is the most consistent finding reported in the literature. It usually appears in the second trimester; hence, it was not seen in the first case. Its association with this syndrome may be as high as 50%.

Placental mesenchymal dysplasia and placentalomegaly, present in cases 1 and 2, respectively, are findings strictly associated with BWS. Placental mesenchymal dysplasia is manifested by a hydropic placenta with multiple cyst-like villi and absence of trophoblastic hyperplasia. This placental anomaly, despite occurring in pregnancies with normal fetuses, in about 25% of cases is associated with BWS [22,23].

The etiology of placental mesenchymal dysplasia is unknown, but some authors suggest that it may be a complex mechanism caused by a mosaicism of uniparental disomy, which would explain its link to BWS [24].

After identifying these anomalies, namely at the ultrasound level, it is essential to review the parental family history. Diagnosis can be confirmed by molecular/cyto genetic tests. The genetics of BWS is complex and may be associated with epigenetic and/or genomic alterations in 2 imprinted domains on chromosome 11p15.5 (also known as the BWS critical region), which regulation may be disrupted by any one of numerous mechanisms. The BWS critical region includes 2 domains: imprinting center 1 (IC1) regulates the expression of IGF2 and H19 in domain 1; imprinting center 2 (IC2) regulates
the expression of CDKN1C, KCNQ1OT1, and KCNQ1 in domain 2. Genomic imprinting is a phenomenon whereby the DNA of the 2 alleles of a gene is differentially modified and only one parental allele is normally expressed [25]. Differential methylation of IC1 and IC2 is associated with expression of specific genes on the paternal and maternal alleles in unaffected individuals. In more than 80% of individuals with BWS, genetic testing can detect alterations in 1 of the 5 following situations: loss of methylation of IC2 on the maternal chromosome, gain of methylation of IC1 on the maternal chromosome, paternal uniparental disomy of 11p15.5, genomic imbalances involving chromosome 11p15.5 (duplications, inversions or translocations visible in conventional cytogenetic or copy number variants as microduplications or microdeletions of 11p15.5 region identified by chromosome microarray analysis and a heterozygous pathogenic variant in gene CDKN1C on maternal allele [26]. Methylation changes may be associated with all, except for pathogenic variants on the maternal CDKN1C allele [27].

Choosing the appropriate test requires understanding the mechanism of disease, as well as having a sufficient knowledge about limitation of the each test.

Prenatal identification of this pathology allows adequate gestational counseling: informing parents about the possibility of TOP, risk of malignancy; determine the best mode of delivery; determine the best approach to potentially fatal neonatal complications such as airway obstruction, hypoglycemia, or congestive heart failure.

This pathology is usually associated with prematurity due to macrosomia and hydramnios. Delivery planning is extremely important, as there is an increased risk of dystocia due to macrosomia. BWS also appears to be associated with an increased risk of postpartum hemorrhage [3].

In addition, families must obtain correct genetic counseling, making it possible to plan a future pregnancy.

In the first case, the molecular study of the CDKN1C gene revealed a likely pathogenic variant, inherited from the mother. The absence of signs and symptoms of BWS in the mother presupposes that the variant is present in the paternal allele, which is silenced by the normal process of imprinting. Therefore, in the first case, the mother had a 50% chance of transmitting the variant to the offspring, with recurrence of BWS, although the phenotype can be variable. In this context, there is room to discuss future reproductive options, such as molecular prenatal diagnosis and preimplantation genetic diagnosis. Other family members, specifically her sisters, whom have a 50% of probability to be carriers are at risk of affected descendants. Her brothers have the same probability to be carriers but there is no risk of affected offspring. However, there is risk of grandchild affected (offspring of daughters). In this context genetic counselling is essential.

In case 2, the search for the methylation status of the 11p15 region by MS-MLPA revealed abnormal methylation, having confirmed the existence of methylation loss in imprinting center 2 and methylation gain in imprinting center 1, compatible with uniparental disomy. The occurrence of uniparental disomy is a generally somatic and post-zygotic event, therefore the probability of recurrence is very low or even negligible, with no risk for other family members [28].

**Conclusions**

Prenatal diagnosis of BWS is extremely important for gestational counseling, perinatal approach and postnatal care, despite its prenatal detection can be challenging.

These cases demonstrate the ultrasound findings existing in this syndrome, as well as the correct diagnostic approach in case of suspicion of this pathology.

The detection of macrosomia, macroglossia, omphalocele, nephromegaly, hydramnios, and placental changes should alert to the possibility of BWS. Furthermore, hypoplasia of the corpus callosum, shortened long bones and foot deformities complement the broad fetal phenotypic spectrum of this pathology.

Positive molecular tests allow to confirm the diagnosis, assess the risk of recurrence, which will vary depending on the causal mechanism, guide reproductive options and surveillance of future pregnancy.

**Patient consent**

Informed consent was obtained from all subjects involved in the study.

**REFERENCES**

[1] Beckwith JB, Perrin EV. In situ neuroblastosomas: a contribution to the natural history of neural crest tumors. Am J Pathol 1963;43:1089–104.

[2] Wiedemann HR. Familial malformation complex with umbilical hernia and macroglossia a “new syndrome”? J Genet Hum 1964;13:223–32.

[3] Pettenati MJ, Haines JL, Higgins RR, Wappner RS, Palmer CG, Weaver DD. Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 1986;74(2):143.

[4] Mussa A, et al. Prevalence of Beckwith-Wiedemann syndrome in North West of Italy. Am J Med Genet A 2013;161A(10):2481.

[5] Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, et al. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005;13:1025.

[6] Enklaar T, Zabel BU, Pratt D. Beckwith-Wiedemann syndrome: multiple molecular mechanisms. Expert Rev Mol Med 2006;8:1.

[7] Elliott M, Bayly R, Cole T, Temple IK, Maher ER. Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet 1994;46:168.

[8] Elliott M, Maher ER. Beckwith-Wiedemann syndrome. J Med Genet 1994;31:560–4.

[9] Brioude F, Kalish JM, Mussa A, Foster AC, Bieck J, Ferrero GB, et al. Expert consensus document: clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol 2018;14(4):229–49. doi:10.1038/nrendo.2017.166.
[10] Weinstein L, Anderson C. In utero diagnosis of Beckwith-Wiedemann syndrome by ultrasound. Radiology 1980;134:474.

[11] Vlijmoen DL, Jaquire Z, Woods DL. Prenatal diagnosis in autosomal dominant Beckwith-Wiedemann syndrome. Prenat Diagn 1991;11(3):167–75.

[12] Williams DH, Gauthier DW, Maizels M. Prenatal diagnosis of Beckwith–Wiedemann syndrome. Prenat Diagn 2005;25:879–84.

[13] Engstrom W, Lindham S, Schofeld P. Wiedemann-Beckwith syndrome. Eur J Pediatr 1988;147:450–7.

[14] Koontz WL, Shaw LA, Lavery JP. Antenatal sonographic appearance of Beckwith-Wiedemann syndrome. J Clin Ultrasound 1986;14:57–9.

[15] Chitayat D, Rothchild A, Ling E, Friedman JM, Couch RM, Yong SL, et al. Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome. Am J Med Genet 1990;36:434–9.

[16] Baird PA, MacDonald EC. An epidemiologic study of congenital malformations of the anterior abdominal wall in more than half a million consecutive live births. Am J Hum Genet 1981;33:470–8.

[17] Chen CP, Chien SC. Prenatal sonographic features of Beckwith-Wiedemann syndrome. Med Ultrasound 2009;21(2):98–106.

[18] Tubbs RS, Oakes WJ. Beckwith-Wiedemann syndrome in a child with Chiari I malformation. Case report. J Neurosurg 2005;103(2 suppl):172–4.

[19] Gardiner K, Chitayat D, Choufani S, Shuman C, Blaser S, Terespolsky D, et al. Brain abnormalities in patients with Beckwith-Wiedemann syndrome. Am J Med Genet A 2012;158A(6):1388–94.

[20] Bui C, Picone O, Mas AE, Levaillant JM, Ami O, Netchine I, et al. Beckwith-Wiedemann syndrome in association with posterior hypoplasia of the cerebellar vermis. Prenat Diagn 2009;29(9):906–7.

[21] Beaufrère A et al. Corpus callosum abnormalities and short femurs in Beckwith–Wiedemann syndrome: a report of two fetal cases. Fetal Pediatr Pathol 2007;26(6):411–417.

[22] Parveen Z, Tongson-Ignacio JE, Fraser CR, Killeen JL, Thompson KS. Placental mesenchymal dysplasia. Arch Pathol Lab Med 2007;131:131–7.

[23] Cohen MC, Roper EC, Sebire NJ, et al. Placental mesenchymal dysplasia associated with fetal aneuploidy. Prenat Diagn 2005;25:187–92.

[24] Pellizzard P. Pathology of the placenta. Case 6. Placental mesenchymal dysplasia. Ann Pathol 2010;30(4):301–5.

[25] Barlow DP. Imprinting: a gamete’s point of view. Trends Genet 1994;10(6):194–9.

[26] Weksberg R, Smith AC, Squire J, Sadowski P. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003;12(Spec No 1):R61–8.

[27] Baskin B, Choufani S, Chen YA, Shuman C, Parkinson N, Lemyre E, et al. High frequency of copy number variations (CNVs) in the chromosome 11p15 region in patients with Beckwith-Wiedemann syndrome. Hum Genet 2014;133(3):321–30.

[28] Shuman C, Beckwith JB, Weksberg R. Beckwith-Wiedemann Syndrome. 2000 Mar 3 [updated 2016 Aug 11]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022.